| Literature DB >> 30057901 |
Miriam R Menezes1, Julien Balzeau1, John P Hagan1.
Abstract
Emerging evidence implicates a wide range of post-transcriptional RNA modifications that play crucial roles in fundamental biological processes including regulating gene expression. Collectively, they are known as epitranscriptomics. Recent studies implicate 3' RNA uridylation, the non-templated addition of uridine(s) to the terminal end of RNA, as a key player in epitranscriptomics. In this review, we describe the functional roles and significance of 3' terminal RNA uridylation that has diverse functions in regulating both mRNAs and non-coding RNAs. In mammals, three Terminal Uridylyl Transferases (TUTases) are primarily responsible for 3' RNA uridylation. These enzymes are also referred to as polyU polymerases. TUTase 1 (TUT1) is implicated in U6 snRNA maturation via uridylation. The TUTases TUT4 and/or TUT7 are the predominant mediators of all other cellular uridylation. Terminal uridylation promotes turnover for many polyadenylated mRNAs, replication-dependent histone mRNAs that lack polyA-tails, and aberrant structured noncoding RNAs. In addition, uridylation regulates biogenesis of a subset of microRNAs and generates isomiRs, sequent variant microRNAs that have altered function in specific cases. For example, the RNA binding protein and proto-oncogene LIN28A and TUT4 work together to polyuridylate pre-let-7, thereby blocking biogenesis and function of the tumor suppressor let-7 microRNA family. In contrast, monouridylation of Group II pre-miRNAs creates an optimal 3' overhang that promotes recognition and subsequent cleavage by the Dicer-TRBP complex that then yields the mature microRNA. Also, uridylation may play a role in non-canonical microRNA biogenesis. The overall significance of 3' RNA uridylation is discussed with an emphasis on mammalian development, gene regulation, and disease, including cancer and Perlman syndrome. We also introduce recent changes to the HUGO-approved gene names for multiple terminal nucleotidyl transferases that affects in part TUTase nomenclature (TUT1/TENT1, TENT2/PAPD4/GLD2, TUT4/ZCCHC11/TENT3A, TUT7/ZCCHC6/TENT3B, TENT4A/PAPD7, TENT4B/PAPD5, TENT5A/FAM46A, TENT5B/FAM46B, TENT5C/FAM46C, TENT5D/FAM46D, MTPAP/TENT6/PAPD1).Entities:
Keywords: 3′ terminal RNA uridylation; DIS3L2; LIN28/let-7 pathway; RNA epitranscritpomics; TUTase; Wilms tumor; cancer; perlman syndrome
Year: 2018 PMID: 30057901 PMCID: PMC6053540 DOI: 10.3389/fmolb.2018.00061
Source DB: PubMed Journal: Front Mol Biosci ISSN: 2296-889X
Figure 1Schematic representation of non-canonical terminal ribonucleotdyl transferases in humans. These enzymes contain a DNA polymerase β-like nucleotidyltransferase domain and a more C-terminal polyA polymerase-like domain that is required for enzymatic activity. TUT1, TUT4, and TUT7 are the primary polymerases responsible for terminal 3′ RNA uridylation in mammalian cells. Other family members lack a critical histidine that confers UTP specificity and are thought to be primarily adenyltransferases. TUT1 has a nuclear localization signal and functions in part in nuclear U6 snRNA maturation and recycling. TUT4 and TUT7 are predominantly cytoplasmic proteins where they function in noncoding RNA quality control, mRNA turnover (both polyadenylated mRNAs and histone mRNAs), and regulation of let-7 microRNA biogenesis with LIN28A.
Nomenclature of Non-canonical terminal ribonucleotidyl transferases.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| TUT4 | Terminal Uridylyl Transferase 4 | ZCCHC11 | TENT3A, PAPD3, KIAA0191 | Cytoplasm (Heo et al., | Numerous Cancer Types including breast, ovarian, and colon (Hallett and Hassell, | U |
| TUT7 | Terminal Uridylyl Transferase 7 | ZCCHC6 | TENT3B, PAPD6, KIAA1711 | In Critical region for Cutaneous Malignant Melanoma Predisposition Locus (Cannon-Albright et al., | U | |
| TUT1 | Terminal Uridylyl Transferase 1, U6 snRNA-specific | TUT1 | PAPD2, STAR-PAP, RBM21 | Nucleolus (Trippe et al., | U and A | |
| TENT2 | Terminal Nucleotidyltransferase 2 | PAPD4 | GLD2, TUT2 | Cytoplasm/Nucleus (Nakanishi et al., | A or A, U, G | |
| TENT4A | Terminal Nucleotidyltransferase 4A | PAPD7 | POLS, TRF4-1, POLK, LAK-1 | Nucleoplasm > Cytoplasm (Ogami et al., | A | |
| TENT4B | Terminal Nucleotidyltransferase 4B | PAPD5 | TRF4-2 | Nucleus/Nucleolar (Lubas et al., | A | |
| MTPAP | Mitochondrial poly(A) polymerase | MTPAP | TENT6, PAPD1, SPAX4 | Mitochondrion (Tomecki et al., | spastic ataxia autosomal recessive type 4 (SPAX4) [OMIM: | A |
Effective date for HUGO-approved change in gene nomenclature was April 12, 2018.
Figure 2Maturation of U6 snRNA. After transcription by RNA polymerase III, the La protein binds the four uridines at the 3′ end. The black dot at the 5′ end represents the gamma-monomethylguanosine triphosphate cap. The La protein is replaced by TUT1 which adds about 20 uridines to the encoded four. The exonuclease and phosphodiesterase USB1 (MPN1) removes the uridines, keeping five of them and adding a terminal 2′, 3′ cyclic phosphate. This 3′ structure facilitates the recruitment of the LSm2-8 complex and protects the U6 snRNA from degradation by the exosome.
Figure 3Maturation of let-7 miRNAs. Newly transcribed pri-let-7 is cleaved first in the nucleus by the Drosha/DGCR complex to generate pre-let-7. After export ot the cytoplasm, pre-let-7 can be recognize by the LIN28A protein by its GGAG sequence in the loop. LIN28A recruits via its Zinc knuckle domain (ZKD), TUT4 on its LIN28 interacting module (LIM). The catalytic module (CM) of TUT4 adds a polyU tail to pre-let-7. The resultant this polyU tail blocks Dicer cleavage and is recognized by the exonuclease DIS3L2 that degrades polyuridylated pre-let-7. In the absence of LIN28A, TUT4 and/or TUT7 add only one uridine at the 3′ end, promoting recognition and cleavage by Dicer/TRBP complex. The mature let-7 produced interacts with Ago2, enters in the RISC complex, and base-pairs with its mRNA targets to promote mRNA degradation and/or translational inhibition.
Figure 4Biogenesis of miR-451. (A) Sequence and secondary structure of human pre-miR-451. The location of Drosha and Ago2 cleavage are noted. Uridylation and 3′ trimming ultimately give rise to mature miR-451 as denoted in red font. (B) Biogenesis of miR-451 compared to canonical miRNA biogenesis. Compared to the canonical pathway wherein pre-miRNA is processed by Dicer, miR-451 undergoes Ago-2 cleavage that allows for processing to yield mature miR-451 independently of Dicer.
Figure 5Pathways leading to mirtron biogenesis. Splicing can generate three types of mirtrons. Introns are spliced and the lariat is debranched to allow folding into pre-miRNA-like hairpins. Splicing also leads to tailed mirtrons which undergo additional trimming step after splicing and debranching. For 5′ mirtrons, trimming is carried out by an unknown nuclease while for 3′ mirtrons, trimming is carried out by the exosome. After export to the cytoplasm, the pre-miRNA hairpins are cleaved by Dicer and loaded onto Argonaute complexes.
Figure 6Degradation of polyadenylated mRNAs. Polyadenylated transcripts transit the nucleus into the cytoplasm through the Exportin 5 complex and then binds polyA binding protein (PABP) on its tail. The mRNA can be directly degraded by decapping with DCP1/2 or endonucleolytic cleavage by XRN1 or by the Exosome/DCPS complex. In addition, mRNA deadenylation by CCR4/NOT or PAN2/3 leaves a short poly(A) tail. After deadenylation, the mRNA can be degraded by uridylation-dependent and independent mechanism that rely XRN1/LSM1-7/DCP1/2 or the Exosome/DCPS complex. For uridylated transcripts, TUT7 and/or TUT4 are responsible for uridine addition and their loss stabilizes many mRNAs. DIS3L2 plays a minor role in degradation of uridylated mRNAs since only 1–3 uridines are added to mRNAs with short polyA-tails.
Figure 7Degradation of histone mRNAs. Upon completion of the cell cycle, stem loop binding protein is phosphorylated and histone mRNAs ending in a stem loop are processed by 3′ hExo. Recruitment of TUTase(s) oligouridylates this structure and initiates degradation of uridylated intermediates either by decapping and/or by the exosome.